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1  | INTRODUC TION
The outcomes of childhood cancer have improved over the last three 
decades with a significant decrease in mortality from 6.5 to 2 per 
100 000 patients.1 However, cardiovascular complications continue 
to be the major causes of morbidity and late mortality in pediatric 
cancer survivors.2 The etiology of cardiotoxicity in cancer survivors 
is multifactorial, with anthracycline exposure, other chemothera‐
peutic agents, radiation therapy, and comorbidities such as hyper‐
tension, diabetes mellitus, and coronary artery disease being major 
risk factors.3,4 Left ventricle (LV) dysfunction, ranging from asymp‐
tomatic dysfunction to symptomatic heart failure, can occur during 
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Purpose: We compared the left ventricular (LV) systolic function in children with can‐
cer before initiation of chemotherapy with matched controls using speckle tracking 
echocardiography.
Methods and results: In this retrospective study, we analyzed the echocardiograms 
of 89 cancer patients before the initiation of chemotherapy and 82 age‐ (8.4 ± 5.2 vs. 
8.9 ± 3.9 years, P = .4) and gender‐matched (64% vs. 67%, males, P = .4) healthy con‐
trols.	Peak	systolic	LV	longitudinal	strain	(LS)	was	significantly	lower	in	cancer	patients	
in	apical	two	(−19.8	±	3.0	vs.	−23.5	±	4.0,	P	<	.001),	three	(−19.4	±	3.2	vs.	−23.4	±	4.0,	
P	<	.001),	and	four‐chamber	views	(−19.7	±	3.4	vs.	−22.5	±	3.0,	P < .001) compared to 
controls,	as	was	global	longitudinal	strain	(GLS)	(−19.8	±	2.7	vs.	−23.4	±	3.2,	P < .001). 
The prechemotherapy group also had a higher E/e' ratio compared to controls at the 
septal (9.3 ± 3.9 vs. 7.9 ± 1.7, P = .005) and lateral annulus (7.9 ± 3.3 vs. 5.9 ± 1.4, 
P < .001) of the mitral valve. The LV ejection fraction was lower in cancer patients 
compared to controls (63.5 ± 4.9 vs. 66.8 ± 4.1, P < .001), although still within normal 
limits. There were no differences in LV myocardial performance index (0.30 ± 0.05 vs. 
0.30 ± 0.09, P < .65) and shortening fraction (35.8 ± 5.2 vs. 36.1 ± 6.1, P < 0.75) be‐
tween the two groups. Subgroup analysis showed no difference in LV GLS between 
patients	with	solid	tumors	(n	=	56)	and	blood	cancers	(n	=	33)	(GLS	−19.2	±	2.9	vs.	
19.5 ± 2.4, P > 0.05).
Conclusion: Our data demonstrating abnormalities in LV GLS in pediatric cancer pa‐
tients even prior to initiation of chemotherapy are novel and perplexing. Further lon‐
gitudinal follow‐up is required to assess the implications of this abnormal LV function 
in these patients.
K E Y W O R D S
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chemotherapy or many years after the completion of chemotherapy. 
Echocardiography is the most commonly used noninvasive tool to 
assess LV function. LV ejection fraction (EF) and shortening fraction 
(SF) are currently used measures of assessment of systolic function 
in cancer patients before, during, and many years after completion 
of chemotherapy.5	Both	these	conventional	echocardiographic	pa‐
rameters are limited in that they are dependent upon LV preload and 
afterload.
Speckle tracking echocardiography (STE) is a relatively newer 
technique which quantifies global and regional myocardial function 
by measuring the myocardial deformation in different phases of the 
cardiac cycle. Studies have shown that STE can detect abnormalities 
in LV function before changes in conventional echo parameters in 
various populations including cancer survivors exposed to cardio‐
toxic chemotherapy.6,7 STE is reproducible and has been shown to 
be independent of the preload, patient age, angle of interrogation, 
and ventricular geometry.8
A	 few	 studies	 in	 adult	 patients	with	 cancer	 have	 reported	 the	
presence of LV dysfunction prior to initiation of chemotherapy. This 
finding is associated with a higher incidence of symptomatic heart 
failure and mortality following chemotherapy.6,9,10	 Assuncao	 et	 al	
compared 76 adult patients with acute leukemia and 76 patients 
without cancer matched for age, gender, hypertension, and the pres‐
ence of diabetes. Leukemia patients had a lower global longitudinal 
strain and higher LV mass and volumes compared to matched pa‐
tients without cancer, even before receiving chemotherapy.11	Adult	
patients, however, have other risk factors for cardiovascular disease 
including diabetes mellitus, systemic hypertension, and coronary 
artery disease, which are very rare in children. The prevalence of 
LV systolic dysfunction in children with malignancies before the ini‐
tiation of chemotherapy and its implications remain unknown. The 
primary aim of this study was to evaluate LV systolic function by STE 
in children with malignancies before starting chemotherapy, in com‐
parison with matched controls. Our secondary aims were as follows: 
(a) to compare LV systolic function (EF and FS) and diastolic function 
(E/A	ratio	and	tissue	Doppler‐derived	E/e'	ratio)	 in	cancer	patients	
before starting chemotherapy with healthy controls (b) to compare 
global	function	by	myocardial	performance	index	(MPI)	in	cancer	pa‐
tients before starting chemotherapy and healthy controls, and (c) to 
compare various echocardiographic parameters between groups of 
patients with solid and hematological malignancies.
2  | METHODS
This was a single‐center, observational study conducted at the 
Children's	 Hospital	 of	Michigan.	 Children	 (≤18	 years	 of	 age)	 diag‐
nosed with a malignancy who had an echocardiogram performed 
before	 the	 initiation	of	 chemotherapy	between	 January	2014	and	
October 2016 were included as the "prechemotherapy group." 
Patients	with	 (a)	 congenital	 heart	 defects	 (except	 patent	 foramen	
ovale), (b) dilated cardiomyopathy, (c) hemodynamically significant 
pericardial effusion, (d) metabolic disorders, and (5) patients who 
had poor quality images were excluded from the study. We also 
excluded patients in whom more than 2 segments were not traced 
properly (n = 4). Healthy normal children who presented to the 
cardiology clinic for evaluation of musculoskeletal chest pain, in‐
nocent murmurs, and vasovagal syncope and had normal electro‐
cardiograms and echocardiograms served as controls. The study 
was approved by the Wayne State University School of Medicine 
and	Detroit	Medical	Center	Institutional	Review	Board.	Chart	review	
was performed and clinical data including, age, gender, and diagnosis 
of malignancies were recorded. Malignancies were subdivided into 
(a) solid tumors which included Wilm's tumor, lymphomas, osteosar‐
comas, and rhabdomyosarcoma and (b) hematological malignancies 
such as acute lymphoblastic leukemia and acute myeloid leukemia. 
Laboratory parameters including complete blood count with differ‐
ential (including hemoglobin, hematocrit, platelets, and mean cor‐
puscular volume), lactate dehydrogenase (LDH), serum uric acid, and 
serum ferritin were collected and compared between patients with 
solid and hematological malignancies.
2.1 | Echocardiographic Data
2.1.1 | LV systolic function and LV mass
The LV ejection fraction was calculated using the modified 
Simpson's method (biplane method of disk) from apical 4‐chamber 
(Ch)	and	2‐Ch	views	as	 recommended	by	 the	American	Society	of	
Echocardiography	 and	 European	 Association	 of	 Echocardiography	
and	 the	 formula	 LVEF	 =	 (End‐diastolic	 volume	 −	 End‐systolic	 vol‐
ume)/End‐diastolic volume.12 The SF was calculated using LV (in‐
ternal, septal, and posterior wall) diameters in end‐diastole and 
end‐systole on conventional M mode echocardiography and the 
standard	 formula	 (LV	 end‐diastolic	 dimension	 −	 LV	 end‐systolic	
dimension)/LV end‐diastolic dimension. 13 LV mass was calculated 
from the M mode measurements using the Devereux formula and 
was indexed to the subject's height (cm)2.7 LV mass = 0.8{1.04[([LVE
Dd	+	IVSd	+	PWd]3	−	LVEDd3)]}	+	0.6	where	LVEDd,	IVSd,	and	PWd	
represent LV, interventricular septal, and posterior wall thickness in 
diastole, respectively.14
2.1.2 | LV diastolic function
For assessment of diastolic function, the ratio of the velocity of early 
diastolic filling (E) to the velocity of diastolic filling due to atrial con‐
traction	 (A)	was	measured	 from	the	spectral	Doppler	of	LV	 inflow	
(E/A)	(Figure	1A).	Tissue	Doppler‐derived	velocities	of	the	septal	and	
the lateral annulus of the mitral valve due to early diastolic filling 
(e'), diastolic filling due to atrial contraction (a'), and velocity due to 
ventricular systole (s') were analyzed as well (Figure 1C).13
2.1.3 | LV global function
Global	LV	function	was	assessed	using	MPI,	calculated	as	the	ratio	
of the sum of the time spent in isovolumetric contraction (ICT) and 
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relaxation phase (IRT) divided by the ejection time (ET) as shown in 
Figure	1B.15
2.1.4 | Speckle Tracking Echocardiography
The	 echocardiograms	 were	 performed	 using	 iE	 33	 (Phillips)	 and	
stored in compressed Digital Imaging and Communication in 
Medical (DICOM) format for offline analysis. Two‐dimensional 
peak systolic longitudinal strain (LS) was measured using vendor‐
independent	software	(2D	Cardiac	Performance	Analysis,	Tom	Tec	
Imaging Systems). The images were analyzed using the single best 
loop from the apical 2‐Ch, 3‐Ch, and 4‐Ch views. The LV endocar‐
dial border was traced semi‐automatically in systole. The images 
were played and tracings were manually adjusted when appropri‐
ate. The software measured the LS from 2‐Ch, 3‐Ch, and 4‐Ch 
views and calculated the global peak systolic longitudinal strain 
(GLS) as an average of these three values (Figure 2). These analyses 
were performed by a single reader who was blinded to clinical de‐
tails (GK).
2.2 | Statistical Analysis
Continuous variables were expressed as mean (SD), median (IQR), 
and categorical variables were expressed as number (%). The 
two groups with and without malignancy were compared using 
Student's t test, Chi‐square test, and Mann–Whitney U test as ap‐
propriate. Subgroup analyses included a comparison of biochemi‐
cal markers and echocardiographic parameters in the groups with 
solid and hematologic malignancies using nonparametric Mann–
Whitney U test. Linear regression analysis was performed to iden‐
tify risk factors associated with abnormal GLS, adjusting for age 
and gender. The intra‐class correlation coefficient (ICC) was cal‐
culated to assess the inter‐observer variability in a random sam‐
ple	of	20	patients.	Statistical	analyses	were	performed	using	SPSS	
F I G U R E  1  Spectral	(A	and	B)	and	tissue	Doppler	(C)	imaging	of	the	mitral	valve
F I G U R E  2   Longitudinal strain with 
bull's eye plot measured from 4‐chamber 
view
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version	21	(SPSS,	Chicago,	IL,	USA),	and	significance	was	defined	
by p‐value < 0.05.
3  | RESULTS
Our cohort consisted of a total of 171 patients, of whom 89 (52%) 
were cancer patients who had an echocardiogram performed be‐
fore initiation of chemotherapy, and 82 (48%) were healthy controls. 
The two groups were comparable in age (Mean (SD) 8.4 ± 5.2 vs. 
8.9 ± 3.9 years, P = .4), weight (34.1 ± 24.3 vs. 36.8 ± 19.3 Kg, P = .43) 
and gender distribution (64% vs. 67% males, P = .40) as shown in 
Table	1.	Among	the	89	patients	in	the	prechemotherapy	group,	56	
(62.9%) had solid tumors and 33 (37.1%) had hematological tumors; 
the different sub‐types of tumors are summarized in Table 2.
3.1 | Prechemotherapy group vs. healthy controls
3.1.1 | Conventional echocardiography
The pediatric cancer patients had a lower LV EF compared to the 
matched healthy controls (63.5 ± 4.9 vs. 66.8 ± 4.1, P < .001), al‐
though still within normal limits. The SF (35.8 ± 5.2 vs. 36.1 ± 6.1, 
P = .75), LV mass indexed to Ht2.7 (36.9 ± 19.2 vs. 32.5 ± 9.1, 
P	=	.06),	and	MPI,	a	marker	of	global	LV	function	(0.30	±	0.05	vs.	
0.30 ± 0.09, P = .65), were not significantly different between 
groups. The prechemotherapy group of patients had a smaller 
LV internal diameter in diastole (3.9 ± 0.8 vs. 4.15 ± 0.7, P = .02), 
higher E/e' ratio at the septal (9.3 ± 3.9 vs. 7.9 ± 1.7, P = .005) and 
lateral annulus (7.9 ± 3.3 vs. 5.9 ± 1.4, P < .001) of the mitral valve 
and	lower	E/A	ratio	(1.6	±	0.48	vs.	2.3	±	0.72,	P < .001), compared 
to healthy controls (Table 3).
3.1.2 | Speckle tracking echocardiography
The LS was significantly lower in the prechemotherapy group com‐
pared	 to	healthy	 controls	 in	 the	2‐Ch	 (−19.8	±	3.0	 vs.	 −23.5	±	4.0,	
P	<	.001),	3‐Ch	(−19.4	±	3.2	vs.	−23.4	±	4.0,	P < .001), and 4‐Ch views 
(−19.7	±	3.4	vs.	−22.5	±	3.0,	P < .001) as shown in Table 3 and Figure 3. 
Also,	GLS	was	significantly	lower	in	the	prechemotherapy	group	com‐
pared	to	the	healthy	controls	(−19.8	±	2.9	vs.	−23.4	±	3.2,	P	<	.001).	A	
total of 26 (29%) cancer patients had a GLS lower than the 5th per‐
centile	(−18.75)	of	healthy	controls.	On	regression	analysis,	we	found	
that a diagnosis of cancer was independently associated with abnor‐
malities in GLS, after adjusting for age and gender (Table 4).
3.1.3 | Inter‐observer Variability
The intra‐class correlation coefficient (ICC) for LS was 0.94 (95% 
confidence interval 0.86‐0.98, f value 17.16, P < .001) indicating 
minimal inter‐observer variability.
3.2 | Solid vs. Hematological malignancies
There were no differences in age, weight, height, heart rate, and 
blood pressure between patients with solid (n = 56) and hemato‐
logical	 malignancies	 (n	 =	 33)	 (Table	 5).	 Patients	 with	 hematologi‐
cal tumors had a higher white count, were more anemic, and had 
significantly higher LDH (P = .003), uric acid (P < .001), and ferritin 
(P < .001) compared to those with solid tumors (Table 6).
3.2.1 | Conventional echocardiography
Spectral and tissue Doppler‐derived measurements of diastolic 
function	 such	 as	 E/A	 ratio,	 E/e'	 ratio	 at	 the	 septal	 and	 the	 lateral	







(n = 82) P
Age	(y) 8.4 (5.2) 8.9 (3.9) .4
Gender (male) 57 (64%) 55 (67%) .4
Weight (kg) 34.1 (24.3) 36.8 (19.3) .43
Height (cm) 125 (33) 134.3 (27.1) .046* 
Systolic	BP	
(mm Hg)
108 (15) 107 (13) .8
Diastolic	BP	
(mm Hg)
64 (12) 61 (8) .08
*P < .05 
TA B L E  2   Distribution of different types of solid and 
hematological tumors
Type of malignancy n (%)
Solid tumors (n = 56, 62.9%)
Neuroblastoma 9 (10.1)
Osteosarcoma 8 (9.0)
Hodgkin's lymphoma 8 (9.0)
Wilm's tumor 7 (7.9)
T‐cell Lymphoblastic lymphoma 6 (6.7)
Rhabdomyosarcoma 4 (4.5)
Ewing sarcoma 3 (3.4)
Burkitt	lymphoma 3 (3.4)
Embryonal sarcoma 2 (2.2)
Hepatoblastoma 2 (2.2)
Ependymoma 1 (1.1)
Small round cell tumor 1 (1.1)
Hepatocellular carcinoma 1 (1.1)
Basal	cell	carcinoma 1 (1.1)
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annulus of the mitral valve, and LV systolic function measured by 
EF and SF were not significantly different among patients with solid 
and	hematological	tumors.	Even	though	MPI	was	statistically	differ‐
ent between the two subgroups, it was in the normal range for both 
groups (Table 5).
3.2.2 | Speckle tracking echocardiography
LV LS measured from 2‐Ch, 3‐Ch, and 4‐Ch views and GLS were not 
different between these groups (Table 5).
4  | DISCUSSION
The present study demonstrates that children with cancers have ab‐
normal LV systolic function, reflected by decrease in peak systolic 
longitudinal strain (LS) in different planes (2‐Ch, 3‐Ch, and 4‐Ch api‐
cal views) as well as a decrease in global longitudinal strain (GLS) 
prior to exposure to chemotherapy when compared to matched 
healthy controls. The diagnosis of cancer was independently associ‐
ated with abnormalities in GLS, after adjusting for the patient's age 
and gender. Interestingly, all the patients had normal conventional 
parameters	such	as	SF	and	MPI.	Our	findings	are	similar	to	recently	
published	results	in	adults	(median	age:	56	years)	by	Assuncao	et	al	
of	lower	GLS	(−19.3	±	2.7	vs.	20.9	±	1.9,	P < .001) but similar LV EF 
(62 ± 6 vs. 62 ± 5, P = .34) in the group with acute leukemia compared 
to matched patients without cancer.11
In adults with cancers, a baseline abnormal strain prior to 
initiating chemotherapy has been shown to be associated with 
adverse cardiovascular risk following chemotherapy.9,16	 Ali	 et	 al	
followed 450 adult leukemia patients for a median duration of 
159 days (range 13‐2891 days) after the start of chemotherapy 
and found that 28 (6%) patients had cardiac events (defined as 
death or symptomatic heart failure with a decrease in EF (58 ± 10 
vs. 62 ± 7, P	=	.005)).	Patients	with	cardiac	events	had	significantly	
lower	prechemotherapy	GLS	(−15	±	2.8%	vs.	−19.7	±	2.7,	P < .001). 
Interestingly,	 absolute	 GLS	 <−17.5%	 was	 associated	 with	 a	 six‐
fold increase in cardiac events.9	Among	2234	adult	patients	with	
breast and hematological cancers, 158 (7%) had LVEF of 50%‐59% 
before initiation of chemotherapy.16 Over a median duration of 
659 days, 12 (7.6%) patients in this group developed major ad‐
verse cardiac events (heart failure or death) at a median duration 
of	173	days.	Baseline	GLS	was	 significantly	 lower	 (−16	±	2.5	 vs.	
−17.7	 ±	 2.6,	P = .015) compared to patients without events and 
independently predicted a major adverse cardiovascular event de‐
fined	as	New	York	Heart	Association	class	III,	IV	congestive	heart	
failure or cardiac death (P = .0065).16 In a prospective study of 86 
adults with various malignancies receiving anthracyclines (median 
age 48, range 30‐63.5 years), 6 patients developed a decrease in 
LV EF by more than 10% to below 53% one year after completing 
chemotherapy. GLS measured before initiation of chemotherapy 
was	significantly	lower	(−19.1	vs.	−21.2,	P = .042) in the group that 
developed anthracycline‐induced cardiotoxicity compared to the 
group that did not.17	 Abnormal	 LV	 systolic	 function,	 defined	 by	
LVEF less than 55%, was noted in 12 of 88 (13%) patients with 
breast cancer and leukemia even before the initiation of chemo‐
therapy. These patients had higher mortality and comprised 40% 
(4 out of 10 total deaths) of the mortality after chemotherapy com‐





(n = 82) P
LV 2‐Ch LS −19.8	(3.0) −23.5	(4.0) <.001* 
LV 3‐Ch LS −19.4	(3.2) −23.4	(4.0) <.001* 
LV 4‐Ch LS −19.7	(3.4) −22.5	(3.0) <.001* 
LV GLS −19.8	(2.7) −23.4	(3.2) <.001* 
LV EF % 63.5 (4.9) 66.8 (4.1) <.001* 
LV FS % 35.8 (5.2) 37.7 (11.2) .15
LVIDD (cm) 3.9 (0.8) 4.15 (0.7) .02* 
LV mass indexed to Ht2.7 36.9 (19.2) 32.5 (9.1) .06
E/A	ratio 1.6 (0.48) 2.3 (0.72) .001* 
E/e' septal 9.3 (3.9) 7.9 (1.7) .005* 
E/e' lateral 7.9 (3.3) 5.9 (1.4) <.001* 
MPI 0.30 (0.05) 0.30 (0.09) .65
Abbreviations:	LV,	left	ventricle;	Ch,	chamber;	LS,	peak	systolic	longitudinal	strain;	GLS,	average	
peak systolic longitudinal strain; EF, ejection fraction; FS, fractional shortening; LVIDD, left ventric‐
ular	internal	diameter	in	diastole;	E,	velocity	of	early	diastolic	filling	of	the	left	ventricle;	A,	velocity	
of diastolic filling of the left ventricle due to atrial contraction; e’, tissue Doppler‐derived velocity 
of	the	septal	and	the	lateral	annulus	of	the	mitral	valve	due	to	early	diastolic	filling;	MPI,	myocardial	
performance index.
*P < .05 
TA B L E  3   Echocardiographic 
parameters in prechemotherapy group 
and healthy controls
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Changes in the LV GLS from baseline have been noted in 
early phases of chemotherapy and also have been shown to be 
associated with subsequent LV dysfunction during follow‐up. 
Asymptomatic	patients	(n	=	19)	who	received	anthracycline	(mean	
dose, 296 ± 103 mg/m2) therapy showed a significant decrease in 
LV GLS at 4 (change 8.7% ±0.2%, P = .033) and 8 months (change 
9.2 ± 0.3%, P	=	 .015)	 from	 their	baseline	value	 (−19.9	±	2.1)	 and	
compared to age‐ and gender‐matched controls (20.5 ± 1.5%, 
P = .011). LV EF decreased significantly at 8 months (4.3 ± 0.1%, 
P = .044) and correlated with the segmental changes in the mid 
and apical LV longitudinal peak systolic strain.7	Among	43	breast	
cancer patients, 8 developed cardiotoxicity at 6 months following 
the start of chemotherapy, defined as more than 5% decrease in 
LV EF to < 55% in symptomatic heart failure or more than 10% 
decrease	 in	 asymptomatic	 patients.	 A	 decrease	 in	 longitudinal	
(−20.5	±	2.2	to	−19.3	±	2.4,	P = .01) and radial (55 ± 12 to 52 ± 12, 
P = .02) strain, from baseline to 3 months independently predicted 
cardiotoxicity at 6 months.6
STE is becoming increasingly popular in the assessment of sub‐
clinical	LV	dysfunction.	Abnormalities	in	strain	are	reported	to	occur	
even	before	changes	in	conventional	echo	parameters.	A	meta‐anal‐
ysis of one retrospective and 15 prospective studies involving 5721 
patients with heart failure, myocardial infarction, valvular heart 
diseases, has shown that decrease in global longitudinal strain is 
independently associated with mortality and has superior prognos‐
tic value to LV EF.19 STE is accurate and validated as a measure of 
F I G U R E  3  Box	and	Whisker	plot	comparing	global	longitudinal	strain	(A),	longitudinal	strain	in	2‐chamber	(B),	3‐chamber	(C),	and	4‐
chamber views (D) between healthy controls and cancer patients
(A) (B)
(C) (D)
TA B L E  4   Regression analysis showing association between 







0.42 1.86, 3.98 <.001
Age 0.12 −0.02,	0.21 .11
Gender 0.03 −0.91,	1.32 .73
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myocardial strain.8,20	The	American	Society	of	echocardiography	and	
European	Association	of	Cardiovascular	 imaging	 recommend	serial	
measurements of global longitudinal strain, ideally beginning from 
prior to initiation of chemotherapy. The global longitudinal strain is 
an ideal deformation parameter in the early detection of subclinical 
LV dysfunction defined as >15% decrease from the baseline value.21
In the current study, we found evidence of a difference in 
diastolic	 function	 parameters	 (E/e'	 and	 E/A	 ratio)	 in	 cancer	 pa‐
tients	and	controls.	Also,	 the	E/e'	 ratio	was	higher	 in	cancer	pa‐
tients at the septal (9.3 ± 3.9 vs. 7.2 ± 1.6) and the lateral annulus 
(7.9 ± 3.3 vs. 5.8 ± 1.9) of the mitral valve, compared to previously 
published values in 55 healthy children between 6 and 9 years. 
22	Corresponding	mean	E/A	ratios	were	1.6	±	0.48	 in	our	cancer	
cohort, 2.3 ± 0.72 in the controls, and 1.99 ± 0.51 in the published 
normative study. However, the clinical significance of these dif‐
ferences in values is uncertain and whether they indicate subtle 
diastolic dysfunction cannot be established.
Diastolic dysfunction in adult cancer patients exposed to chemo‐
therapy has been reported previously.23	A	pediatric	study	reported	
normal	diastolic	function,	as	assessed	by	E/A	ratio	of	2.1	±	4.3,	septal	
E/E' ratio of 7.2 ± 2 and lateral E/E' ratio of 5.5 ± 1.2, in 63 cancer 
patients aged 13.7 ± 4.5 years, 5 years from completion of anthra‐
cycline chemotherapy with a median cumulative dose of 165 (range 
45‐520) mg/m2 .24	 In	 contrast,	 an	 increase	 in	MPI	with	 increasing	
doses of anthracycline exposure from 200 to 300 mg/m2 dose has 
been demonstrated.15 However, data on diastolic function or global 
myocardial performance in pediatric cancer patients before initiating 
chemotherapy	are	 lacking.	 In	our	 study,	MPI	was	 similar	 in	cancer	
patients and healthy controls.
4.1 | Effect of Hematological cancer vs. 
Solid cancers
In our study, there were no significant differences in GLS in patients 
with leukemia and solid tumors. This is in contrast to the reported 
higher abnormalities in adults with leukemia, compared to solid tu‐
mors. In a subgroup analysis, 28 women with leukemia showed sig‐
nificantly	lower	GLS	(−19.4	±	3%	vs.	−21.2	±	2.2%),	compared	to	28	
women	with	breast	cancer	and	 (−21.5	±	2.1%)	noncancer	patients,	
with no differences in LV volumes and mass.11	Ali	et	al	 reported	a	
higher incidence of symptomatic heart failure and cardiac death in 
adults with acute leukemia (10 of 80, 13%) compared to lymphoma 
(18 of 370, 5%) following anthracycline treatment.
4.2 | Plausible etiology for prechemotherapy LV 
dysfunction
Several factors may explain the abnormalities in LV function before 
the initiation of chemotherapy. Inflammatory mediators have been 
postulated to play a role in LV remodeling. In animal models, changes 
in the expression of TNF and total matrix metalloproteinase inhibi‐
tor activities have been associated with LV dilation or remodeling.25 
Alternatively,	 infiltration	 of	 the	 myocardium	 by	 circulating	 cancer	
cells could cause cardiac dysfunction. In an autopsy study of 420 
hearts with leukemia, leukemic infiltrates and hemorrhage were ob‐
served in 69%. LV was the second most common location of leuke‐
mic infiltrates (36%) after pericardium (39%).26
In this novel study of LV function in pediatric cancer patients be‐
fore initiation of chemotherapy, abnormal LV systolic deformation, 
as evidenced by changes in strain parameters, was detected even 
though conventional echocardiographic systolic parameters were 
mostly within the normal range. We also demonstrated alteration 






tumors (n = 33) P
Age	(y) 8.8 (5.3) 7.7 (5.3) .36
Height (cm) 127 (32.5) 121.7 (34.1) .47
Weight (kg) 33.8 (21.8) 34.5 (29.3) .91
LV 2‐Ch LS −18.6	(3.2) −19.7	(3) .3
LV 3‐Ch LS −19.2	(4) −19.1	(2.9) .9
LV 4‐Ch LS −19.2	(3.6) −18.7	(4) .6
LV GLS −19.2	(2.9) −19.5	(2.4) .7
MPI 0.31 (0.05) 0.28 (0.05) .04* 
E/A	ratio 1.69 (0.5) 1.63 (0.4) .5
E/e' Septal 9.6 (4.7) 8.9 (1.8) .4
E/e’ lateral 7.9 (3.9) 7.7 (1.7) .7
Ejection 
Fraction
63.6 (5.1) 63.2 (4.5) .75
Shortening 
Fraction
36.5 (5) 34.8 (4.5) .1
Abbreviations:	LV,	left	ventricle;	Ch,	chamber;	LS,	peak	systolic	longitu‐
dinal strain; GLS, average peak systolic longitudinal strain; E, velocity of 
early	diastolic	filling	of	the	left	ventricle;	A,	velocity	of	diastolic	filling	
of the left ventricle due to atrial contraction; e’, tissue Doppler‐derived 
velocity of the septal and the lateral annulus of the mitral valve due to 
early	diastolic	filling;	MPI,	myocardial	performance	index.
*P < .05 






tumors (n = 33) P
Hemoglobin (g/dL) 11.4 (3.6) 8.4 (3.3) <.001* 
WBC	(×103	cells/
mm3)
10.2 (9.4) 57.2 (82.8) <.001* 
Platelets	(×103	cells/
mm3)
304 (138) 89 (110) <.001* 
Retic count (%) 1.8 (1.2) 0.98 (0.7) <.001* 
Ferritin (ng/mL) 51.5 (31) 401(309) <.001* 
LDH (units/L) 548 (482) 1344 (1670) .002* 
Uric acid (mg/dL) 3.7 (1.4) 5.9 (3) <.001* 
Abbreviations:	LDH,	lactate	dehydrogenase;	WBC,	white	blood	cell	
count;	Retic,	reticulocyte,	ng,	nanogram;	mL,	milliliter;	L—liter.
*P < .05 
1734  |     AKAM‐VENKATA ET Al.
in diastolic function as measured by the E/e' ratio in this group. The 
prechemotherapy global longitudinal strain may serve as an import‐
ant risk stratification tool in identifying cancer patients who are at 
risk for subsequent chemotherapy‐related cardiovascular toxicity. 
These patients may need closer monitoring and may benefit from 
prompt intervention or prophylactic treatment.
4.3 | Limitations
The present study is limited by its retrospective nature and single‐
center data. Even though this is retrospective data, we had sufficient 
quality echocardiographic images to measure the longitudinal strain 
in different planes from apical 2‐Ch, 3‐Ch, and 4‐Ch images as well as 
global longitudinal strain. In our center, all cancer patients undergo 
echocardiographic evaluation before starting anthracycline‐based 
chemotherapy. However, cancer patients not receiving anthracycline 
chemotherapy may have been missed. Data on markers of inflamma‐
tion (cytokines, C reactive protein, and erythrocyte sedimentation 
rate), cardiac biomarkers ( N‐terminal pro‐brain natriuretic peptide, 
cardiac troponins, and creatine kinase) were not available in cancer 
patients before initiation of chemotherapy. Our study was designed 
to evaluate the presence of abnormal GLS in the prechemotherapy 
setting; therefore, longitudinal follow‐up to assess the prognostic 
implications of our findings was not performed.
5  | CONCLUSION
Our study concludes that abnormal LV systolic global longitudinal 
strain is present in a significant number of children with cancer prior 
to	exposure	to	chemotherapeutic	agents.	A	larger	multicenter	 lon‐
gitudinal follow‐up study is needed to validate our results and as‐
sess the utility of prechemotherapy strain in identifying those at risk 
of post‐chemotherapy‐cardiotoxicity. Further investigation into the 
etiology and prevention of abnormal GLS even before exposure to 
chemotherapy in cancer patients is needed.
CONFLIC T OF INTERE S T
The authors declare that they have no conflict of interest.
E THIC AL APPROVAL
This article does not contain any studies with human participants or 
animals performed by any of the authors. The study was approved 
by the Wayne State University School of Medicine and Detroit 
Medical	Center	Institutional	Review	Board.
INFORMED CONSENT
Not applicable. Waiver of consent obtained through Wayne 
State University School of Medicine and Detroit Medical Center 
Institutional	Review	Board.
ORCID
Jyothsna Akam‐Venkata  https://orcid.
org/0000‐0001‐8625‐6020 
R E FE R E N C E S
	 1.	 AmericanCancerSociety.	 Cancer	 Facts	 &	 Figures	 2017.	 Available	
from: https ://www.cancer.org/conte nt/dam/cancer‐org/resea rch/
cancer‐facts‐and‐stati stics/ annual‐cancer‐facts‐and‐figur es/2017/
cancer‐facts‐and‐figur es‐2017.pdf
	 2.	 Mertens	AC,	 Liu	Q,	Neglia	 JP,	 et	 al.	Cause‐specific	 late	mortality	
among 5‐year survivors of childhood cancer: the childhood cancer 
survivor study. J Natl Cancer Inst. 2008;100(19):1368‐1379.
	 3.	 Gilladoga	AC,	Manuel	C,	Tan	C,	Wollner	N,	Sternberg	SS,	Murphy	
ML. The cardiotoxicity of adriamycin and daunomycin in children. 
Cancer. 1976;37(2 Suppl):1070‐1078.
	 4.	 Lipshultz	 SE,	Adams	MJ,	Colan	SD,	 et	 al.	 Long‐term	cardiovascu‐
lar toxicity in children, adolescents, and young adults who receive 
cancer therapy: pathophysiology, course, monitoring, management, 
prevention, and research directions: a scientific statement from the 
American	Heart	Association.	Circulation. 2013;128(17):1927‐1995.
 5. Children'sOncologyGroup. Long‐Term Follow‐up Guidelines for 
Survivors	of	Childhood,	Adolescent	and	Young	Adult	Cancer	2013,	
October	[Version	4.0].	Available	from:	http://www.survi	vorsh	ipgui	
delin es.org/pdf/LTFUG uidel ines_40.pdf
	 6.	 Sawaya	H,	Sebag	IA,	Plana	JC,	et	al.	Early	detection	and	prediction	
of cardiotoxicity in chemotherapy‐treated patients. Am J Cardiol. 
2011;107(9):1375‐1380.
	 7.	 Poterucha	 JT,	Kutty	S,	 Lindquist	RK,	 Li	 L,	Eidem	BW.	Changes	 in	
left ventricular longitudinal strain with anthracycline chemotherapy 
in adolescents precede subsequent decreased left ventricular ejec‐
tion fraction. J Am Soc Echocardiogr. 2012;25(7):733‐740.
	 8.	 Lorch	SM,	Ludomirsky	A,	Singh	GK.	Maturational	and	growth‐related	
changes in left ventricular longitudinal strain and strain rate measured 
by two‐dimensional speckle tracking echocardiography in healthy 
pediatric population. J Am Soc Echocardiogr. 2008;21(11):1207‐1215.
	 9.	 Ali	MT,	Yucel	E,	Bouras	S,	et	al.	Myocardial	strain	is	associated	with	
adverse clinical cardiac events in patients treated with anthracy‐
clines. J Am Soc Echocardiogr. 2016;29(6):pp. 522–7 e3.
	10.	 Negishi	 K,	 Negishi	 T,	 Hare	 JL,	 Haluska	 BA,	 Plana	 JC,	 Marwick	
TH. Independent and incremental value of deformation indices 
for prediction of trastuzumab‐induced cardiotoxicity. J Am Soc 
Echocardiogr. 2013;26(5):493‐498.
	11.	 Assuncao	B,	Handschumacher	MD,	Brunner	AM,	et	al.	Acute	 leu‐
kemia is associated with cardiac alterations before chemotherapy. J 
Am Soc Echocardiogr. 2017;30(11):1111‐1118.
	12.	 Lang	RM,	Badano	LP,	Mor‐Avi	V,	et	al.	Recommendations	for	cardiac	
chamber quantification by echocardiography in adults: an update 
from	the	American	society	of	echocardiography	and	the	European	
association of cardiovascular imaging. J Am Soc Echocardiogr. 
2015;28(1):pp. 1–39 e14.
	13.	 Lopez	L,	Colan	SD,	Frommelt	PC,	et	al.	Recommendations	for	quan‐
tification methods during the performance of a pediatric echocar‐
diogram: a report from the pediatric measurements writing group 
of	 the	 American	 society	 of	 echocardiography	 pediatric	 and	 con‐
genital heart disease council. J Am Soc Echocardiogr. 2010;23(5):pp. 
465–95; quiz 576–7.
	14.	 Khoury	PR,	Mitsnefes	M,	Daniels	SR,	Kimball	TR.	Age‐specific	ref‐
erence intervals for indexed left ventricular mass in children. J Am 
Soc Echocardiogr. 2009;22(6):709‐714.
	15.	 Eidem	BW,	Sapp	BG,	Suarez	CR,	et	al.	Usefulness	of	the	myocardial	
performance index for early detection of anthracycline‐induced 
cardiotoxicity in children. Am J Cardiol.	2001;87(9):pp.	1120–2,	A9.
     |  1735AKAM‐VENKATA ET Al.
	16.	 Mousavi	N,	Tan	TC,	Ali	M,	Halpern	EF,	Wang	L,	Scherrer‐Crosbie	
M. Echocardiographic parameters of left ventricular size and func‐
tion as predictors of symptomatic heart failure in patients with a 
left ventricular ejection fraction of 50–59% treated with anthracy‐
clines. Eur Heart J Cardiovasc Imaging. 2015;16(9):977‐984.
	17.	 Charbonnel	C,	Convers‐Domart	R,	Rigaudeau	S,	et	al.	Assessment	
of global longitudinal strain at low‐dose anthracycline‐based che‐
motherapy, for the prediction of subsequent cardiotoxicity. Eur 
Heart J Cardiovasc Imaging. 2017;18(4):392‐401.
	18.	 Yoon	GJ,	Telli	ML,	Kao	DP,	Matsuda	KY,	Carlson	RW,	Witteles	RM.	
Left ventricular dysfunction in patients receiving cardiotoxic can‐
cer therapies are clinicians responding optimally? J Am Coll Cardiol. 
2010;56(20):1644‐1650.
	19.	 Kalam	K,	Otahal	P,	Marwick	TH.	Prognostic	implications	of	global	LV	
dysfunction: a systematic review and meta‐analysis of global longi‐
tudinal strain and ejection fraction. Heart. 2014;100(21):1673‐1680.
	20.	 Amundsen	BH,	Helle‐Valle	T,	Edvardsen	T,	et	al.	Noninvasive	myo‐
cardial strain measurement by speckle tracking echocardiography: 
validation against sonomicrometry and tagged magnetic resonance 
imaging. J Am Coll Cardiol. 2006;47(4):789‐793.
	21.	 Plana	JC,	Galderisi	M,	Barac	A,	et	al.	Expert	consensus	for	multimo‐
dality imaging evaluation of adult patients during and after cancer 
therapy:	a	report	from	the	American	Society	of	Echocardiography	
and	the	European	Association	of	Cardiovascular	Imaging.	J Am Soc 
Echocardiogr. 2014;27(9):911‐939.
	22.	 Eidem	BW,	McMahon	CJ,	Cohen	RR,	et	al.	Impact	of	cardiac	growth	
on Doppler tissue imaging velocities: a study in healthy children. J 
Am Soc Echocardiogr. 2004;17(3):212‐221.
	23.	 Honda	K,	Takeshita	K,	Murotani	K,	et	al.	Assessment	of	left	ventricu‐
lar diastolic function during trastuzumab treatment in patients with 
HER2‐positive breast cancer. Breast Cancer. 2017;24(2):312‐318.
	24.	 Harahsheh	 A,	 Aggarwal	 S,	 Pettersen	 MD,	 L’Ecuyer	 T.	 Diastolic	
function in anthracycline‐treated children. Cardiol Young. 
2015;25(6):1130‐1135.
 25. Sivasubramanian N, Coker ML, Kurrelmeyer KM, et al. Left ventric‐
ular remodeling in transgenic mice with cardiac restricted overex‐
pression of tumor necrosis factor. Circulation. 2001;104(7):826‐831.
	26.	 Roberts	 WC,	 Bodey	 GP,	 Wertlat	 PT.	 Wertlake	 PT.	 The	 heart	
in	 acute	 leukemia.	 A	 study	 of	 420	 autopsy	 cases.	 Am J Cardiol. 
1968;21(3):388‐412.
How to cite this article:	Akam‐Venkata	J,	Kadiu	G,	Galas	J,	
Aggarwal	S.	Pediatric	Malignancies:	Is	the	Prechemotherapy	
Left Ventricular Function Normal? Echocardiography. 
2019;36:1727–1735. https ://doi.org/10.1111/echo.14461 
